EpimAb Biotherapeutics Announces the First CTA Filing of a FIT-IG® Bispecific Antibody by its License Partner Almirall

Core Insights - EpimAb Biotherapeutics has achieved its first Clinical Trial Application (CTA) filing through its partnership with Almirall, marking a significant milestone for the company [1] - Almirall has licensed EpimAb's FIT-Ig platform to develop bispecific antibodies, with the first candidate targeting IL-13 and OX-40L for atopic dermatitis expected to enter Phase 1 clinical trials in the first half of 2026 [2] - The FIT-Ig technology allows for the generation of bispecific antibodies using basic structural components of monoclonal antibodies, demonstrating the platform's versatility and potential for rapid drug development [3] Company Overview - EpimAb Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing multi-specific antibodies, leveraging its proprietary FIT-Ig and MAT-Fab platforms to advance a unique pipeline targeting cancer and autoimmune diseases [4]